Efficacy of targeted FasL in nasopharyngeal carcinoma (Q40609109)

22 September 2017

Efficacy of targeted FasL in nasopharyngeal carcinoma (English)

1 reference

22 September 2017

15

1 reference

22 September 2017

Brian O'Sullivan

11

0 references

author name string

Jian-Hua Li

1

1 reference

22 September 2017

Wei Shi

2

1 reference

22 September 2017

Marie Chia

3

1 reference

22 September 2017

Otto Sanchez-Sweatman

4

1 reference

22 September 2017

Christopher Siatskas

5

1 reference

22 September 2017

Dolly Huang

6

1 reference

22 September 2017

Pierre Busson

7

1 reference

22 September 2017

Henry Klamut

8

1 reference

22 September 2017

Wen-Chen Yeh

9

1 reference

22 September 2017

Chris Richardson

10

1 reference

22 September 2017

Pat Gullane

12

1 reference

22 September 2017

Peter Neligan

13

1 reference

22 September 2017

Jeff Medin

14

1 reference

22 September 2017

1 December 2003

1 reference

22 September 2017

1 reference

22 September 2017

8

1 reference

22 September 2017

6

1 reference

22 September 2017

964-973

1 reference

Radiotherapy alone in patients with advanced nasopharyngeal cancer: comparison with an intergroup study. Is combined modality treatment really necessary?

22 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

Limitation of conventional two dimensional radiation therapy planning in nasopharyngeal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: results of a meta-analysis of 1,528 patients from six randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

The effects of combining ionizing radiation and adenoviral p53 therapy in nasopharyngeal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

Adenovirus-p53 gene therapy in human nasopharyngeal carcinoma xenografts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

Cisplatin chemotherapy plus adenoviral p53 gene therapy in EBV-positive and -negative nasopharyngeal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

Cancer gene therapy: fringe or cutting edge?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

Proliferation, cell cycle and apoptosis in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

Programmed cell death: alive and well in the new millennium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

Downregulation of Fas ligand by shedding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

Restricted expression of an adenoviral vector encoding Fas ligand (CD95L) enhances safety for cancer gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

Cytogenetic studies on an epithelial cell line derived from poorly differentiated nasopharyngeal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

Adenoviruses as expression vectors and recombinant vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

Establishment and characterization of three transplantable EBV-containing nasopharyngeal carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

Gene transfer of Fas ligand induces tumor regression in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

Death receptors: signaling and modulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

The kiss of death: promises and failures of death receptors and ligands in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

Dissecting the pathways to death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

Lysosomal protease pathways to apoptosis. Cleavage of bid, not pro-caspases, is the most likely route

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

Granzyme B short-circuits the need for caspase 8 activity during granule-mediated cytotoxic T-lymphocyte killing by directly cleaving Bid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

Death the Fas way: regulation and pathophysiology of CD95 and its ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

Radiation-induced expression of functional Fas ligand in EBV-positive human nasopharyngeal carcinoma cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

The biochemistry of apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

Defying death after DNA damage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

Replicative adenoviruses for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

The membrane-bound but not the soluble form of human Fas ligand is responsible for its inflammatory activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

Gene therapy: trials and tribulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.08.018

10.1016/J.YMTHE.2003.08.018

7 January 2021

Identifiers

DOI

1 reference

22 September 2017

1 reference